CN1097005A - 2-cyano-3-hydroxy acrylamides and preparation thereof and purposes - Google Patents
2-cyano-3-hydroxy acrylamides and preparation thereof and purposes Download PDFInfo
- Publication number
- CN1097005A CN1097005A CN94100187A CN94100187A CN1097005A CN 1097005 A CN1097005 A CN 1097005A CN 94100187 A CN94100187 A CN 94100187A CN 94100187 A CN94100187 A CN 94100187A CN 1097005 A CN1097005 A CN 1097005A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- group
- cyclopropyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to new 2-cyano-3-hydroxy acrylamides, their preparation method, contain their pharmaceutical composition and they are as the purposes of medicine, particularly in the chronic inflammatory diseases of treatment human or animal's rheumatoid arthritis, immunity or non-immunogenic and the purposes aspect the cancer.Wherein R, R
1, R
2, R
3, A, B, E definition described with specification sheets.
Description
The present invention relates to new 2-cyano-3-hydroxy acrylamides, their preparation method contains their pharmaceutical composition and they are as the purposes of medicine.
One aspect of the present invention provides logical formula I compound and base addition salt thereof:
Wherein
A, B and E represent group=CH-or nitrogen-atoms separately, and its condition is that at least one represents nitrogen-atoms among A, B or the E;
R representative contain 3 to 6 carbon atoms cycloalkyl, contain the alkenyl of 2 to 6 carbon atoms or contain the alkynyl of 2 to 6 carbon atoms;
R
1Represent hydrogen atom or contain the alkyl of 1 to 3 carbon atom;
R
2And R
3Can represent hydrogen atom, halogen atom, NO identical or different and separately
2Base, cyano group, contain 1 to 6 carbon atom the straight or branched alkyl, contain 3 to 6 carbon atoms cycloalkyl, contain 1 to 6 carbon atom the straight or branched alkoxyl group, contain 1 to 6 carbon atom the straight or branched alkylthio ,-CO-R
4Group (R wherein
4Represent hydrogen atom, contain 1 to 6 carbon atom straight or branched alkyl or contain the cycloalkyl of 3 to 6 carbon atoms) or be selected from-(CH
2)
m-CX
3,-O-(CH
2)
m-CX
3,-S-(CH
2)
m-CX
3,-O-(CX
2)
m-CX
3With-S-(CX
2)
m-CX
3Group (wherein m represent 0,1,2 or 3 and X represent halogen atom), perhaps R
2And R
3Representative-O-CH together
2-O-group.
Should be appreciated that the present invention extends to whole tautomers of formula I compound.
Term described herein " alkyl that contains 1 to 3 carbon atom " expression methyl, ethyl, propyl group or sec.-propyl.
Term described herein " alkyl that contains 1 to 6 carbon atom " expression, for example, butyl, amyl group or the hexyl of methyl, ethyl, propyl group or sec.-propyl or expression straight or branched.
Term described herein " cycloalkyl that contains 3 to 6 carbon atoms " representative ring propyl group, cyclobutyl, cyclopentyl or cyclohexyl.
Term described herein " alkoxyl group that contains 1 to 6 carbon atom " expression, for example, butoxy, pentyloxy or the hexyloxy of methoxyl group, oxyethyl group, propoxy-or isopropoxy or expression straight or branched.
Term described herein " alkylthio that contains 1 to 6 carbon atom " expression, for example, butylthio, the own sulfenyl of penta sulfenyl of methylthio group, ethylmercapto group, rosickyite base or iprotiazem base or expression straight or branched.
Term described herein " halogen atom " comprises fluorine, chlorine, bromine or iodine atom and preferably refers to fluorine, chlorine or bromine atom.
The following formula group preferably represented in term described herein " alkenyl that contains 2 to 6 carbon atoms "
The following formula group preferably represented in term described herein " alkynyl that contains 2 to 6 carbon atoms "
Following radicals can be used as group-(CH
2)
m-CX
3,-O-(CH
2)
m-CX
3,-S-(CH
2)
m-CX
3,-O-(CX
2)
m-CX
3With-S-(CX
2)
m-CX
3Example:
-CF
3，-（CH
2）-CF
3，-（CH
2）
2-CF
3，-（CH
2）
3-CF
3，
-O-CF
3，-O-（CH
2）-CF
3，-O-（CH
2）
2-CF
3，-O-（CH
2）
3-CF
3
-S-CF
3，-S-（CH
2）-CF
3，-S-（CH
2）
2-CF
3，-S-（CH
2）
3-CF
3
-O-（CF
2）-CF
3，-S-CF
2-CF
3
The group of following formula structure:
Comprise, for example, following groups:
N-(2-chloropyridine-5-yl)-, N-(4-methyl-5-nitro pyridine-2-yl)-, N-(5-5-flumethiazine-2-yl)-, N-(5-chloropyridine-2-yl)-, N-(5-bromopyridine-2-yl)-, N-(5-nitropyridine-2-yl)-, the N-(pyridin-4-yl)-and N-(3,5-dichloropyridine-2-yl)-.
Described base addition salt can for the inorganic or formed salt of organic bases, the salt that forms with mineral alkali for example, salt as sodium, potassium, lithium, calcium, magnesium and ammonium, or the salt that forms with organic bases, described organic bases has for example methylamine, propylamine, Trimethylamine 99, diethylamine, triethylamine, N, N-dimethylethanolamine, three (methylol) aminomethane, thanomin, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, PROCAINE HCL, PHARMA GRADE, Methionin, arginine, group amino and N-methylglucosamine.
Preferred The compounds of this invention be wherein R represent cyclopropyl or following formula group and A, B, E, R
1, R
2And R
3Compound as defined above,
Further preferred The compounds of this invention is R wherein
1Represent hydrogen atom or methyl and R, A, B, E, R
2And R
3Compound as defined above.
Particularly preferred The compounds of this invention is the compound as giving a definition, wherein
R
1Represent hydrogen atom or methyl;
R
2And R
3Can identical or differently represent hydrogen, chlorine or bromine atom separately, or cyano group, nitro, methyl, cyclopropyl, methoxyl group or methylthio group ,-CO-R
4Group (R wherein
4Represent hydrogen atom, methyl or cyclopropyl) or group-(CH
2)
m-CF
3,-O-(CH
2)
m-CF
3,-S-(CH
2)
m-CF
3,-O-(CF
2)
m-CF
3Or-S-(CF
2)
m-CF
3(wherein m represents 0,1,2 or 3); Perhaps R
2And R
3Represent group-O-CH together
2-O-; And the definition of A, B, E and R is the same.
More particularly preferred The compounds of this invention is represented cyclopropyl, R for R wherein
1Represent hydrogen atom or methyl, R
2And R
3Can represent hydrogen, chlorine or bromine atom or methyl, nitro or trifluoromethyl identical or different and separately, A, B and the same compound of E definition.
Especially preferred compound is:
2-cyano group-3-cyclopropyl-3-hydroxy-n-(2-chloropyridine-5-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(4-methyl-5-nitro pyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-trifluoromethyl-pyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-chloropyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-bromopyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-nitropyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(pyridin-4-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(3,5-dichloropyridine-2-yl)-2-acrylamide;
And base addition salt.
The compounds of this invention for example, can prepare as follows, and these methods have constituted another aspect of the present invention.
For example, the formula I compound can prepare by one of following two kinds of methods as defined above:
A) make the formula II compound
(wherein A, B, E, R
1, R
2And R
3As above definition) with sodium hydride reaction (, in the presence of catalyzer, carrying out), subsequently with products therefrom and the reaction of formula III compound if suitable:
(wherein on behalf of halogen atom and R, Hal as above define); Or
B) make formula II compound and formula (III as defined above
A) the compound reaction,
(wherein Hal represents halogen atom and R
ARepresentative has the group of R as defined above of protecting group in addition) obtain formula (I
A) compound,
(R wherein
A, A, B, E, R
1, R
2And R
3As above definition), slough protecting group subsequently and obtain wherein R formula I compound as defined above.
Wherein R representative contain the cycloalkyl of 3 to 6 carbon atoms and other group the formula I compound also can be by making formula IV compound and highly basic prepared in reaction as defined above,
Wherein A, B, E, R
1, R
2, R
3As above define with R.
Under arbitrary situation of aforesaid method, if desired, the formula I compound of gained can change into its additive salt subsequently according to a conventional method thus.
Reaction between formula II compound and the sodium hydride is preferably in anhydrous organic solvent such as tetrahydrofuran (THF) or methylene dichloride exists down and, if suitable, can with the catalyzer of sodium hydride solvation for example imidazoles in the presence of carry out.
The reaction product of formula II compound and sodium hydride and formula III or (III
A) between reaction be preferably in anhydrous organic solvent such as tetrahydrofuran (THF) or methylene dichloride exists down, under envrionment temperature or low temperature, carry out.Optimum temps is about 25 ℃ and be about 0 ℃ under the other situation in some cases; Optimum temps is between-80 ℃ and-50 ℃ in other cases.
Formula III or (III
A) compound is preferably chloride of acid or acid fluoride.As what the formula III examples for compounds can be mentioned the propine acyl fluorides arranged; This compound can pass through, and for example, makes propynoic acid and benzoyl fluoride prepared in reaction and distills in the subsequent reaction mixture.
Work as R
ARepresentative is when having the R group of protecting group in addition, and this protecting group can be, for example, and arylseleno such as phenylseleno.The deprotection of this class protecting group can be by for example utilizing superoxide such as hydrogen peroxide, in the presence of solvent-free or organic solvent for example in the presence of the mixture of ethanol/methylene oxidation finish.
Reaction between formula IV compound and the highly basic is preferably under the reflux temperature of reaction media to be carried out.
The formula II compound can prepare as follows: in the presence of dicyclohexylcarbodiimide or phosphorus pentachloride, in the presence of anhydrous organic solvent such as tetrahydrofuran (THF) or methylene dichloride, make the reaction of formula (V) compound and cyanoacetic acid,
Wherein A, B, E, R
1, R
2And R
3As above definition.
Embodiment subsequently describes in the part, and the two reaction table that all exists of above-mentioned dicyclohexylcarbodiimide and anhydrous tetrahydro furan is shown method A; The two subsequently embodiment of being reflected at that exists of above-mentioned phosphorus pentachloride and anhydrous methylene chloride describes in the part and is expressed as method B.
By being similar to/method described in the WO91/17748, the formula IV compound can react with the formula VI chloride of acid by formula (V) compound as defined above and make.
The chloride of acid of formula VI can be made by corresponding acid.Described acid can be according to the preparation of method described in the document for example, and the method for particularly press No. the 326107th, European patent prepares.
The formula I compound is characterized in that tart.The base addition salt of formula I compound is suitable to making inorganic by proximate stoichiometric ratio or organic bases and formula I compound react and prepare.Above-mentioned salt can prepare under the situation of not separating corresponding acidic cpd intermediate.
The compounds of this invention has very useful pharmacological properties.It should be noted that their significant anti-inflammatory activities especially.They both can suppress the Inflammatory response that caused by stimulant, can be activated and tardy anaphylaxis by the immunocyte that specific antigens causes by retardance again.
These character partly further specify at embodiment.
So formula I compound and base addition salt useful as drug thereof.
Another aspect of the present invention has provided on formula I compound as defined above and the pharmacology thereof acceptable base addition salt as the purposes of medicine.
The The compounds of this invention that is preferably used as medicine is that wherein R represents cyclopropyl or following formula group and A, B, E, R
1, R
2And R
3Compound as defined above.
The compound that also is preferably used as medicine is R wherein
1Represent hydrogen atom or methyl and R, A, B, E, R
2And R
3The compounds of this invention as defined above.
What be preferably used as medicine especially is such The compounds of this invention, wherein
R
1Represent hydrogen atom or methyl;
R
2And R
3Can represent identical or different and separately hydrogen, chlorine or bromine atom or cyano group, nitro, methyl, cyclopropyl, methoxyl group or methylthio group ,-CO-R
4Group (R wherein
4Represent hydrogen atom, methyl or cyclopropyl) or group-(CH
2)
m-CF
3,-O-(CH
2)
m-CF
3,-S-(CH
2)
m-CF
3,-O-(CF
2)
m-CF
3Or-S-(CF
2)
m-CF
3(wherein m represents 0,1,2 or 3); Or
R
2And R
3Represent group-O-CH together
2-O-; And
A, B, E and R as above define.
The more special The compounds of this invention that is preferably used as medicine is such compound, and wherein R represents cyclopropyl, R
1Represent hydrogen atom or methyl, R
2And R
3Can represent hydrogen, chlorine or bromine atom or methyl, nitro or trifluoromethyl identical or different and separately, A, B and E as above define.
Especially the The compounds of this invention that is preferably used as medicine is following compound:
2-cyano group-3-cyclopropyl-3-hydroxy-n-(2-chloropyridine-5-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(4-methyl-5-nitro pyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-trifluoromethyl-pyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-chloropyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-bromopyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-nitropyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(pyridin-4-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(3,5-dichloropyridine-2-yl)-2-acrylamide;
And their base addition salt.
For example, these medicines can be used for treating rheumatoid arthritis, the chronic inflammatory diseases (as graft versus host disease, allograft reaction, uveitis) and the cancer of immune and non-immunogenic.
Usually dosage is different and change along with compound used therefor, the patient who needs treatment and described patient's disease, for the dosage of oral administration can for, for example, every day 0.1mg to 200mg.
Another aspect of the present invention has provided pharmaceutical composition, and said composition comprises as acceptable diluent, carrier and/or vehicle on acceptable base addition salt at least a compound of formula I as defined above of activeconstituents or its pharmacology and one or more pharmacology of combining with it.
For as for the medicine, formula I compound and base addition salt thereof can be attached to the pharmaceutical composition that is used for oral, rectum or parenteral route administration.
For example, these pharmaceutical compositions can and can be common used formulations in people's medicine for solid or liquid, as conventional tablet or coated tablet, capsule (comprising the gelatine capsule agent), granula, suppository, solution such as injection solution agent; They can prepare according to a conventional method.Described activeconstituents can with common used mixed with excipients in the pharmaceutical composition, described vehicle is just like talcum, Sudan Gum-arabic, lactose, starch, Magnesium Stearate, theobroma oil, fatty substance, alkane derivative, glycols, various wetting agent, dispersion agent or emulsifying agent and sanitas moisture or not aqueous excipient, animal or plant source.
Another aspect of the present invention has provided the method for chronic inflammatory diseases of rheumatoid arthritis, immunity or the non-immunogenic of treatment human or animal body, and this method comprises to the above patient uses acceptable base addition salt on the compound of formula I as defined above of significant quantity or its pharmacology.The present invention is further specified by following non-limiting examples.
The preparation that embodiment 1-8 is raw materials used
The raw material of 2-cyano group-3-cyclopropyl-3-hydroxy-n-(2-chloropyridine-5-yl)-2-acrylamide (embodiment 1)
Method A
In 0 ℃ with cyanoacetic acid (5.95g, 70.0mmol) and dicyclohexylcarbodiimide (14.44g, (9.00g is in anhydrous tetrahydro furan 70.0mmol) (150ml) solution 70.0mmol) to be added to the 5-amino-2-chloropyridine that is stirring.Utilize the tlc monitoring reaction, wait to observe and reaction mixture is filtered after reacting completely and filtrate is evaporated to dried.The gained solid is developed with anhydrous methylene chloride, filters and vacuum-drying, obtains N-(2-chloropyridine-5-yl)-2-malonamide nitrile (10.56g, 77%).
The raw material of following embodiment can be prepared as stated above by the 2-aminopyridine of suitable replacement, has done following indicated variation simultaneously:
The raw material of 2-cyano group-3-cyclopropyl-3-hydroxy-n-(4-methyl-5-nitro pyridine-2-yl)-2-acrylamide (embodiment 2)
This product obtains N-(4-methyl-5-nitro pyridine-2-yl through column chromatography purifying (Sorbsil C60 silicon-dioxide, 60% hexane/40% ethyl acetate))-2-malonamide nitrile (51%).
The raw material of 2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-trifluoromethyl-pyridine-2-yl)-2-acrylamide (embodiment 3)
Utilize cyanoacetic acid (1.2 equivalent) and dicyclohexylcarbodiimide (1.2 equivalent) to carry out above-mentioned reaction, obtain N-(5-5-flumethiazine-2-yl)-2-malonamide nitrile (79%).
The raw material of 2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-chloropyridine-2-yl)-2-acrylamide (embodiment 4)
Use cyanoacetic acid (1 equivalent) and dicyclohexylcarbodiimide (1.1 equivalent) in methylene dichloride, to reflux and carry out this reaction.With the ethyl acetate development, obtain N-(5-chloropyridine-2-yl)-2-malonamide nitrile (90%).
The raw material of 2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-bromopyridine-2-yl)-2-acrylamide (embodiment 5)
Method B
(0.22g, (0.54g is in anhydrous methylene chloride 2.60mmol) (8ml) solution 2.60mmol) to be added to the phosphorus pentachloride that is stirring with cyanoacetic acid in 1 minute.Gained solution was refluxed 30 minutes, then with the reactor nitrogen wash.(0.30g 1.73mmol) also continues to reflux to add 2-amino-5-bromopyridine.Utilize the tlc monitoring reaction, question response fully after with in the reaction mixture impouring water (4ml).Stir after 30 minutes, leach N-(5-bromopyridine-2-yl)-2-malonamide nitrile and vacuum-drying (0.27g, 65%).
The raw material of 2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-nitropyridine-2-yl)-2-acrylamide (embodiment 6)
Utilize method B to obtain N-(5-nitropyridine-2-yl by 2-amino-5-nitropyridine)-2-malonamide nitrile (42%).
The raw material of 2-cyano group-3-cyclopropyl-3-hydroxy-n-(3,5-dichloropyridine-2-yl)-2-acrylamide (embodiment 8)
By 2-amino-3, the 5-dichloropyridine makes N-(3 according to method B, 5-dichloropyridine-2-yl)-2-malonamide nitrile (29%).
The preparation of embodiment 1-8
Embodiment 1:2-cyano group-3-cyclopropyl-3-hydroxy-n-(2-chloropyridine-5-yl)-2-acrylamide
Method C
(3.21g, 80% mineral oil dispersion 107.1mmol) are added to the N-(2-chloropyridine-5-yl that is stirring in batches)-(7.00g is in anhydrous tetrahydro furan 35.7mmol) (200ml) solution for the 2-malonamide nitrile with sodium hydride in 0 ℃.Stir after 1 hour, and adding ring third carbonyl chloride (48.6ml, 53.6mmol).The usefulness tlc monitoring reaction process that continues, with (1.25 l) in the reaction mixture impouring water, Dropwise 35 % hcl acidifying stirred 30 minutes then to pH1 after question response was complete.Leach the precipitation that is generated and wash with water.To precipitate then with the ethyl acetate development, filter and vacuum-drying, obtain title compound (7.91g, 83%).
The following example prepares as stated above, and has done the variation of being indicated:
Embodiment 2:2-cyano group-3-cyclopropyl-3-hydroxy-n-(4-methyl-5-nitro pyridine-2-yl)-2-acrylamide
By obtaining crystallization (87%) in the ethyl acetate/hexane.
Embodiment 3:2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-5-flumethiazine-2-yl)-2-acrylamide
By obtaining crystallization (86%) in °-60 ℃ of sherwood oils of ethyl acetate/40.
Embodiment 4:2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-chloropyridine-2-yl)-2-acrylamide
Utilize sodium hydride (2.4 equivalent) and catalytic imidazoles and ring third carbonyl chloride (1.2 equivalent) to carry out this reaction.Recrystallization obtains title compound (91%) in ethyl acetate.
Embodiment 5:2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-bromopyridine-2-yl)-2-acrylamide
Utilize sodium hydride (2.4 equivalent) and catalytic imidazoles and ring third carbonyl chloride (1.2 equivalent) to carry out above-mentioned reaction at 25 ℃.Title compound is developed with ether, filters and vacuum-drying (83%).
Embodiment 6:2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-nitropyridine-2-yl)-2-acrylamide
Utilize sodium hydride (2.4 equivalent) and catalytic imidazoles and ring third carbonyl chloride (1.2 equivalent) to carry out above-mentioned reaction in 25 ℃.Title compound is developed with ether, filters and vacuum-drying (89%).
Embodiment 7:2-cyano group-3-cyclopropyl-3-hydroxy-n-(pyridin-4-yl)-2-acrylamide
Method D
5-cyclopropyl isoxazole-4-carboxylic acid makes by the described method of document (EP 326 107A1).
With 5-cyclopropyl isoxazole-4-carboxylic acid (1.5g, 9.75mmol) and thionyl chloride (20ml) refluxed together 90 minutes.Vacuum-evaporation reaction mixture and with resistates toluene coevaporation.Be dissolved in the chloride of acid that is generated in the anhydrous methylene chloride (10ml) and be added to the 4-aminopyridine that is suspended in the anhydrous methylene chloride (50ml) (1.0g, 6.5mmol) in.Add pyridine (0.77g, 9.75mmol) and with reaction mixture stirring at room 90 minutes.Leach solid product and make it to be dissolved in the methyl alcohol (100ml) adding triethylamine (2ml).Reaction mixture refluxed 1 hour then in the impouring water (200ml), is added concentrated hydrochloric acid and is acidified to pH1.Obtained lenticular solid title compound in 16 hours in 4 ℃ of placements, this solid washes with water and vacuum-drying (0.67g, 45%).
Embodiment 8:2-cyano group-3-cyclopropyl-3-hydroxy-n-(3,5-dichloropyridine-2-yl)-2-acrylamide
According to method C(as described in the embodiment 1), by N-(3,5-dichloropyridine-2-yl)-the 2-malonamide nitrile makes this compound (69%).
The spectroscopic data of embodiment of the invention compound, productive rate, fusing point and ultimate analysis data are provided by the table I.
Embodiment 9
Preparation is corresponding to the tablet of following prescription:
The compound 20mg of embodiment 1
Every tablet of middle vehicle is up to 150mg
(concrete vehicle: lactose, starch, talcum, Magnesium Stearate).
Embodiment 10
Preparation is corresponding to the tablet of following prescription
The compound 20mg of embodiment 2
Every tablet of middle vehicle is up to 150mg
(concrete vehicle: lactose, starch, talcum, Magnesium Stearate).
Pharmacologically active
The biochemical test method:
Test 1: carrageenin big white mouse claw oedema (PO-R)
To several groups of big white mouse (n=6-12, male CFHB, weight range 160-180g) oral administration test compound or control vector, after one hour, the 1mg carrageenin that is dissolved in 0.2ml physiological saline is expelled in the right back vola of big white mouse.In the claw of offside, inject contrast physiological saline.Assessment claw oedema reaction after three hours.
Test 2: delayed hypersensitivity small white mouse claw oedema (DTH-M)
By the emulsion of subcutaneous injection 1mg methylated bovine serum albumin (MBSA) in 0.2ml volume physiological saline/freund complete adjuvant (FCA) with several groups of small white mouses (n=8-10, male CD-1, weight range 25-30g) sensitization.Give negative control group small white mouse injecting normal saline/FCA emulsion.Be used in the right back vola that the 0.1mg MBSA in the 0.5ml volume physiological saline stimulates small white mouse on the 7th day after the sensitization, assessment DTH claw oedema reaction behind the twenty four hours.In the offside claw, inject contrast physiological saline.Test compound or control vector the 4th, 5,6 day every day oral administration once, be administered twice in the 7th day, stimulated last hour and stimulated back 6 hours oral administrations in MBSA.
Test 3: delayed-type hypersensitivity big white mouse claw oedema (DTH-R).
FCA by tail end subcutaneous injection 0.1ml volume is with several groups of big white mouse (n=8-12, male CFHB, weight range 160-180g) sensitization.To negative control group injection incomplete Freund adjuvent.Be used for the right back vola that the 0.1mg MBSA in the 0.4mg mycobacterium tuberculosis extract antigen of 0.2ml volume physiological saline stimulates big white mouse after the sensitization on the 7th day, assessment DTH claw oedema reaction after 24 hours.In the claw of offside, inject contrast physiological saline.Test compound at the 4th, 5,6 day oral administration once was administered twice on the 7th day, in preceding 1 hour of antigenic stimulation and back 6 hours oral administrations of stimulation.
Provide the result of these tests in the table II, wherein provided the percent inhibition that oedema forms.The dosage of giving oral with mg/kg be unit.The table II
The table II
| Embodiment | Test 1 | Test 2 | Test 3 | |||
| Percent inhibition | Dosage | Percent inhibition | Dosage | Percent inhibition | Dosage | |
| 1 | 32 | 50 | Poison 9 | 100 30 | 71 8 | 50 10 |
| 2 | 10 | 50 | 7 | 100 | 48 | 50 |
| 3 | 30 | 10 | 37 | 30 | 88 40 | 10 3 |
| 4 | 18 | 50 | 48 | 100 | 64 | 50 |
| 5 | 11 | 50 | Poison 4 | 100 30 | Poison 66 | 50 10 |
| 6 | -6 | 50 | 27 | 100 | 67 | 50 |
| 7 | -43 | 50 | 22 | 100 | 18 | 50 |
| 8 | -15 | 50 | 9 | 100 | 21 | 50 |
Claims (29)
1, formula I compound and base addition salt thereof:
Wherein
A, B and E represent group=CH-or nitrogen-atoms separately, and its condition is that at least one represents nitrogen-atoms among A, B or the E;
R representative contain 3 to 6 carbon atoms cycloalkyl, contain the alkenyl of 2 to 6 carbon atoms or contain the alkynyl of 2 to 6 carbon atoms;
R
1Represent hydrogen atom or contain the alkyl of 1 to 3 carbon atom;
R
2And R
3Can represent hydrogen atom, halogen atom, NO identical or different and separately
2Base, cyano group, contain 1 to 6 carbon atom the straight or branched alkyl, contain 3 to 6 carbon atoms cycloalkyl, contain 1 to 6 carbon atom the straight or branched alkoxyl group, contain 1 to 6 carbon atom the straight or branched alkylthio ,-CO-R
4Group (R wherein
4Represent hydrogen atom, contain 1 to 6 carbon atom straight or branched alkyl or contain the cycloalkyl of 3 to 6 carbon atoms) or be selected from-(CH
2)
m-CX
3,-O-(CH
2)
m-CX
3,-S-(CH
2)
m-CX
3,-O-(CX
2)
m-CX
3With-S-(CX
2)
m-CX
3Group (wherein m represent 0,1,2 or 3 and X represent halogen atom), perhaps R
2And R
3Representative-O-CH together
2-O-group.
2, as the desired compound of claim 1, wherein R represents cyclopropyl or following formula group:
And A, B, E, R
1, R
2And R
3Definition with claim 1.
3, as claim 1 or 2 desired compound, wherein R
1Represent hydrogen atom or methyl, and R, A, B, E, R
2And R
3Definition with claim 1.
4, as any desired compound of claim 1 to 3,
R wherein
1Represent hydrogen atom or methyl;
R
2And R
3Can be identical or different, and represent hydrogen, chlorine or bromine atom separately, or cyano group, nitro, methyl, cyclopropyl, methoxyl group or methylthio group ,-CO-R
4Group (R wherein
4Represent hydrogen atom, methyl or cyclopropyl) or group-(CH
2)
m-CF
3,-O-(CH
2)
m-CF
3,-S-(CH
2)
m-CF
3,-O-(CF
2)
m-CF
3Or-S-(CF
2)
m-CF
3(wherein m represents 0,1,2 or 3);
Perhaps R
2And R
3Represent group-O-CH together
2-O-; And the definition of R, A, B and E is with claim 1.
5, as any desired compound of claim 1 to 4,
Wherein R represents cyclopropyl;
R
1Represent hydrogen atom or methyl;
R
2And R
3Can be identical or different, represent hydrogen, chlorine or bromine atom or methyl, nitro or trifluoromethyl separately;
The definition of A, B and E is with claim 1.
6, as any desired compound of claim 1 to 5, be selected from:
2-cyano group-3-cyclopropyl-3-hydroxy-n-(2-chloropyridine-5-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(4-methyl-5-nitro pyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-trifluoromethyl-pyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-chloropyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-bromopyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(5-nitropyridine-2-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(pyridin-4-yl)-2-acrylamide;
2-cyano group-3-cyclopropyl-3-hydroxy-n-(3,5-dichloropyridine-2-yl)-2-acrylamide;
And base addition salt.
7, as any desired, the specifically described compound of this paper of claim 1 to 6.
8, as any desired, the specifically described compound of the arbitrary embodiment of this paper of claim 1 to 6.
9, as the preparation method of any desired formula I compound of claim 1 to 8, this method comprises
A) make the formula II compound
(wherein A, B, E, R
1, R
2And R
3Definition with claim 1) with sodium hydride reaction (if be suitably in catalyzer exist down carry out), subsequently products therefrom and formula III compound are reacted:
(wherein Hal represents halogen atom, and the definition of R is with claim 1); Perhaps
B) incite somebody to action formula II compound and formula (III as defined above
A) the compound reaction,
(wherein Hal represents halogen atom and R
ARepresentative has the group of R as defined above of protecting group in addition), obtain formula (I
A) compound,
(R wherein
A, A, B, E, R
1, R
2And R
3As above definition), take off the back protecting group subsequently and obtain wherein R formula I compound as defined above.
10, as the desired method of claim 9, the wherein reaction product of formula II compound and sodium hydride and formula III or (III
A) be reflected at anhydrous tetrahydro furan or methylene dichloride between the compound exist down and carry out under envrionment temperature or low temperature.
11, as claim 9 or 10 desired methods, wherein be reflected at anhydrous tetrahydro furan or the methylene dichloride between formula II compound and the sodium hydride exists down and carries out in the presence of the imidazoles that has as catalyzer.
12, as claim 9 or 11 any desired methods, wherein work as R
AWhen representative had the R group of protecting group in addition, this protecting group was arylseleno such as phenylseleno.
13, as the preparation method of any desired formula I compound of claim 1 to 8, wherein the R representative contains the cycloalkyl of 3 to 6 carbon atoms, and this method comprises makes formula IV compound and highly basic reaction,
Wherein A, B, E, R
1, R
2And R
3Definition the same with the definition of claim 1 and R.
14, as any desired method of claim 9 to 12, wherein the formula II compound is by making formula (V) compound and cyanoacetic acid prepared in reaction,
Wherein, A, B, E, R
1, R
2And R
3Definition with claim 1.
15, as the desired method of claim 14, be reflected at dicyclohexylcarbodiimide or the phosphorus pentachloride of its Chinese style (V) compound and cyanoacetic acid exist down and carry out in the presence of anhydrous tetrahydro furan or methylene dichloride.
16, as the desired method of claim 13, wherein the formula IV compound is by making as the defined formula of claim 14 (V) compound and formula VI chloride of acid prepared in reaction,
Wherein the definition of R is with claim 13.
17, as any desired method of claim 9 to 16, wherein the formula I compound of gained changes into its base addition salt immediately according to a conventional method thus.
18, as the desired method of claim 17, wherein by make base addition salt inorganic or organic bases and formula I compound prepared in reaction formula I compound by proximate stoichiometric ratio.
19, as any desired, the method as described herein substantially of claim 9 to 18.
20, as any desired, the described method of arbitrary embodiment substantially as herein of claim 9 to 18.
21, no matter when by method preparation as described in any one of claim 9 to 20 as any desired formula I compound of claim 1 to 8 or its base addition salt.
22, use in the treatment as claim 1 to 8 or 21 any desired formula I compound or its pharmaceutically useful base addition salt.
23, as medicine as claim 1 to 8 or 21 any desired formula I compound or its pharmaceutically useful base addition salt.
24, as claim 1 to 8 or 21 any desired formula I compounds or pharmaceutically useful base addition salt purposes as medicine.
25, as claim 1 to 8 or 21 any desired formula I compounds or its pharmaceutically useful base addition salt in the chronic inflammatory diseases of treatment rheumatoid arthritis, immunity or non-immunogenic and the purposes aspect the cancer.
26, pharmaceutical composition, said composition contain at least a as claim 1 to 8 or 21 any desired formula I compounds or its pharmaceutically useful base addition salt and one or more acceptable diluents, carrier and/or the vehicle that combine with it as activeconstituents.
27,, substantially as described herein composition desired as claim 26.
28, desired as claim 26, substantially as the described composition of the arbitrary embodiment of this paper.
29, a kind of chronic inflammatory diseases of rheumatoid arthritis, immunity or non-immunogenic for the treatment of human or animal body and the method for cancer, comprise to described human or animal body use significant quantity as claim 1 to 8 or 21 any desired formula I compound or its pharmaceutically useful base addition salt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939300083A GB9300083D0 (en) | 1993-01-05 | 1993-01-05 | Chemical compounds |
| GB9300083.4 | 1993-01-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1097005A true CN1097005A (en) | 1995-01-04 |
| CN1042935C CN1042935C (en) | 1999-04-14 |
Family
ID=10728304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94100187A Expired - Lifetime CN1042935C (en) | 1993-01-05 | 1994-01-04 | Chemical compounds |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5346912A (en) |
| EP (1) | EP0606175B1 (en) |
| JP (1) | JP3334988B2 (en) |
| KR (1) | KR100295717B1 (en) |
| CN (1) | CN1042935C (en) |
| AT (1) | ATE128968T1 (en) |
| AU (1) | AU663017B2 (en) |
| BR (1) | BR9400017A (en) |
| CA (1) | CA2112866C (en) |
| CZ (1) | CZ283948B6 (en) |
| DE (1) | DE69400024T2 (en) |
| DK (1) | DK0606175T3 (en) |
| EE (1) | EE03001B1 (en) |
| ES (1) | ES2078130T3 (en) |
| FI (1) | FI106553B (en) |
| GB (1) | GB9300083D0 (en) |
| GR (1) | GR3017723T3 (en) |
| HR (1) | HRP940006B1 (en) |
| HU (1) | HU216835B (en) |
| IL (1) | IL107788A (en) |
| LT (1) | LT3766B (en) |
| LV (1) | LV10712B (en) |
| MX (1) | MX9400274A (en) |
| NO (1) | NO300839B1 (en) |
| NZ (1) | NZ250520A (en) |
| PL (1) | PL175135B1 (en) |
| RU (1) | RU2126387C1 (en) |
| SI (1) | SI9300686A (en) |
| SK (1) | SK280508B6 (en) |
| TW (1) | TW259785B (en) |
| UA (1) | UA40573C2 (en) |
| YU (1) | YU49047B (en) |
| ZA (1) | ZA939118B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693574A (en) * | 2014-11-25 | 2016-06-22 | 中国科学院大连化学物理研究所 | 2-alkylthioalkenyl amide derivative and synthetic method thereof |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1100495A4 (en) * | 1998-07-28 | 2002-09-25 | Smithkline Beecham Corp | Propenamides as ccr5 modulators |
| EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
| TW200917962A (en) | 2007-08-27 | 2009-05-01 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| US8729083B2 (en) | 2008-09-24 | 2014-05-20 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| JP2012532176A (en) | 2009-07-06 | 2012-12-13 | ビーエーエスエフ ソシエタス・ヨーロピア | Pyridazine compounds for invertebrate pest control |
| BR112012000149B8 (en) | 2009-07-06 | 2021-01-12 | Basf Se | pyridazine compounds, method for controlling invertebrate pests and method for protecting plant propagation material and / or plants |
| US9125414B2 (en) | 2009-07-24 | 2015-09-08 | Basf Se | Pyridine derivatives compounds for controlling invertebrate pests |
| KR20160079123A (en) | 2013-11-22 | 2016-07-05 | 젠자임 코포레이션 | Novel methods for treating neurodegenerative diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL186239B (en) | 1975-06-05 | Hoechst Ag | PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT WITH ANTIFLOGISTICAL AND / OR ANALGETICAL ACTION AND PROCEDURE FOR THE PREPARATION OF A 2-HYDROXYETHYLIDE ENCYANAACETIC ANILIDE SUITABLE FOR USE IN THIS PROCESS. | |
| DE2555789A1 (en) * | 1975-12-11 | 1977-07-07 | Hoechst Ag | Antiinflammatory and analgesic hydroxy-methylene-cyano-acetanilides - prepd. e.g. by reacting cyanoacetanilide derivs. with ortho-esters and hydrolysing |
| US4435407A (en) * | 1982-01-07 | 1984-03-06 | Ciba-Geigy Corporation | Certain substituted β-oxo-α-carbamoylpyrrolepropionitriles |
| DE3534440A1 (en) | 1985-09-27 | 1987-04-02 | Hoechst Ag | DRUGS AGAINST CHRONIC GRAFT VERSUS HOST DISEASES AND AUTO AUTO DISEASES, IN PARTICULAR SYSTEMIC LUPUS ERYTHEMATODES |
| US4888357A (en) | 1988-01-26 | 1989-12-19 | Bristol-Myers Company | Antiarthritic β-cycloalkyl-β-oxopropionitriles |
| IL92508A0 (en) * | 1988-12-08 | 1990-08-31 | Ciba Geigy Ag | Novel alpha-cyano-beta-oxopropionamides |
| KR100188801B1 (en) * | 1990-05-18 | 1999-06-01 | 엥겔하르트 라피체 | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, drugs contaning these compounds and use of such drugs |
| IL99811A (en) * | 1990-10-30 | 1996-03-31 | Roussel Uclaf | 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them |
| IL102790A (en) * | 1991-09-17 | 1996-01-31 | Roussel Uclaf | 3-Cycloalkyl-prop-2- enamide derivatives |
-
1993
- 1993-01-05 GB GB939300083A patent/GB9300083D0/en active Pending
- 1993-11-29 IL IL10778893A patent/IL107788A/en not_active IP Right Cessation
- 1993-12-03 AU AU52130/93A patent/AU663017B2/en not_active Expired
- 1993-12-06 ZA ZA939118A patent/ZA939118B/en unknown
- 1993-12-20 LT LTIP1634A patent/LT3766B/en not_active IP Right Cessation
- 1993-12-20 US US08/170,372 patent/US5346912A/en not_active Expired - Lifetime
- 1993-12-20 NZ NZ250520A patent/NZ250520A/en not_active IP Right Cessation
- 1993-12-24 SI SI9300686A patent/SI9300686A/en unknown
- 1993-12-28 JP JP34951193A patent/JP3334988B2/en not_active Expired - Lifetime
- 1993-12-29 YU YU82593A patent/YU49047B/en unknown
- 1993-12-29 SK SK1495-93A patent/SK280508B6/en not_active IP Right Cessation
- 1993-12-30 CZ CZ932921A patent/CZ283948B6/en not_active IP Right Cessation
-
1994
- 1994-01-03 PL PL94301774A patent/PL175135B1/en unknown
- 1994-01-04 FI FI940031A patent/FI106553B/en not_active IP Right Cessation
- 1994-01-04 ES ES94400009T patent/ES2078130T3/en not_active Expired - Lifetime
- 1994-01-04 BR BR9400017A patent/BR9400017A/en not_active Application Discontinuation
- 1994-01-04 RU RU94000064A patent/RU2126387C1/en active
- 1994-01-04 UA UA94005036A patent/UA40573C2/en unknown
- 1994-01-04 LV LVP-94-02A patent/LV10712B/en unknown
- 1994-01-04 DE DE69400024T patent/DE69400024T2/en not_active Expired - Lifetime
- 1994-01-04 AT AT94400009T patent/ATE128968T1/en active
- 1994-01-04 EP EP94400009A patent/EP0606175B1/en not_active Expired - Lifetime
- 1994-01-04 NO NO940020A patent/NO300839B1/en not_active IP Right Cessation
- 1994-01-04 DK DK94400009.0T patent/DK0606175T3/en active
- 1994-01-04 HR HR9300083.4A patent/HRP940006B1/en not_active IP Right Cessation
- 1994-01-04 KR KR1019940000057A patent/KR100295717B1/en not_active IP Right Cessation
- 1994-01-04 CN CN94100187A patent/CN1042935C/en not_active Expired - Lifetime
- 1994-01-05 HU HU9400033A patent/HU216835B/en unknown
- 1994-01-05 MX MX9400274A patent/MX9400274A/en unknown
- 1994-01-05 CA CA002112866A patent/CA2112866C/en not_active Expired - Lifetime
- 1994-01-31 TW TW083100783A patent/TW259785B/en not_active IP Right Cessation
- 1994-11-14 EE EE9400360A patent/EE03001B1/en unknown
-
1995
- 1995-10-12 GR GR950401071T patent/GR3017723T3/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693574A (en) * | 2014-11-25 | 2016-06-22 | 中国科学院大连化学物理研究所 | 2-alkylthioalkenyl amide derivative and synthetic method thereof |
| CN105693574B (en) * | 2014-11-25 | 2017-12-19 | 中国科学院大连化学物理研究所 | 2 alkylthio group alkenylamide derivatives and its synthetic method |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1043531C (en) | Pyrimidine derivatives and a process for production thereof | |
| CN1066739C (en) | Phosphonic diester deriv | |
| CN1264840C (en) | 8-methoxy-(1,2,4) triazolo (1,5-A) pyridine derivatives and their use as adenosine receptor ligands | |
| CN1309711C (en) | 3-amido-1,2-benzoisoxazole derivatives, process for preparation, and use thereof | |
| CN88101642A (en) | Piperazinyl-heterogeneous ring compound | |
| CN1747942A (en) | Heterocyclic compounds useful as nurr-1 activators | |
| CN86107754A (en) | Thiazole is [4,5-C] quinoline also | |
| CN1195741C (en) | Pyrimidinone compounds, pharmaceutical compositions containing the compounds and the process for preparing the same | |
| CN1278795A (en) | Process for making diaryl pyridines useful as cox-2 inhibitors | |
| CN1305465A (en) | Aryl alkanoylpyridazines | |
| CN1064482A (en) | New 3-cycloalkyl-propanamides, the preparation method of their tautomer and its esters | |
| CN1176908C (en) | Process for producing pyridine derivate | |
| CN1142227A (en) | Novel thiazolidin-4-one derivatives | |
| CN1097005A (en) | 2-cyano-3-hydroxy acrylamides and preparation thereof and purposes | |
| CN1104017A (en) | Substituted (arylalkoxybenzyl) aminopropanamide derivatives, their preparation and use as anti-epileptic, neuroprotective and antidepressant agents | |
| CN1221734A (en) | New naphthalene compounds, process for their preparation and pharmaceutical compositions containing them | |
| CN1711236A (en) | Nitroaniline-based alkylating agents and their use as prodrugs | |
| CN1112365A (en) | Phosphonic diester derivative | |
| CN1105360A (en) | 1-[2H-1-benzopyran-2-one-8yl]-piperazin derivative | |
| CN1258276A (en) | Cyanoguanidines as cell proliferation inhibitors | |
| CN1121389C (en) | Cyanoguanidines as cell proliferation inhibitors | |
| CN1044241C (en) | Oxopyridinylquinoxaline derivative | |
| CN1304383C (en) | Benzothiazole derivatives | |
| CN1564821A (en) | 5-methoxy-8-aryl-[1,2,4]triazolo[1,5-a]pyridine derivatives as adenosine receptor antagonists | |
| CN1261414C (en) | Pyridineamido derivatives as inhibitors of monoamine oxidase (MAO-B) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: LUSUO ROUSSEL UCLAF CO., LTD. Free format text: FORMER NAME OR ADDRESS: ROUSSEL-UCLAF Owner name: VENTIS PHARMA S.A. Free format text: FORMER NAME OR ADDRESS: HOECHST MARION ROUSSEL INC. Owner name: HOECHST MARION ROUSSEL INC. Free format text: FORMER NAME OR ADDRESS: LUSUO ROUSSEL UCLAF CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: French Anthony Patentee after: AVENTIS PHARMA S.A. Address before: French AUX Patentee before: Hoechst Marion Roussel Address after: French Roman Patentee after: Roussel-Uclaf Address before: Paris France Patentee before: ROUSSEL UCLAF Address after: French AUX Patentee after: Hoechst Marion Roussel Address before: French Roman Patentee before: Roussel-Uclaf |
|
| CX01 | Expiry of patent term |
Expiration termination date: 20140104 Granted publication date: 19990414 |
|
| CX01 | Expiry of patent term |